Optimal treatment of clinically node-positive prostate cancer in the PSMA PET/CT era

Appropriate Use of PSMA PET in Clinical PracticeПодробнее

Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate CancerПодробнее

The role of PSMA PET in recurrent prostate cancerПодробнее

Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET ImagingПодробнее

Transforming Prostate Cancer Diagnosis - everyone is getting a PSMA PET/CT📊Подробнее

PSMA-PET scanning and management of cN1 prostate cancerПодробнее

Can PSMA PET scans + traditional tests improve cancer detection?Подробнее

Which Treatment Comes First - Radiation, Hormone, or Chemo? #ProstateCancer #MarkScholzMD #PCRIПодробнее

How to use PSMA-PET/CT in the Management of Relapsing Prostate Cancer Patients Webcast (2023)Подробнее

2021: PSMA and Prostate Imaging | Dr. Thomas Hope | 2021 Moyad + Scholz Mid-Year Update | PCRIПодробнее

Guidelines for using PSMA PET in the staging of prostate cancerПодробнее

#PSMA #PET for BCR Salvage #Radiotherapy #cancer #Prostate #CancerПодробнее

Local and systemic therapies for cN1 prostate cancerПодробнее

PSMA PET/CT Imaging | Appropriate Use Criteria | SNMMIПодробнее

Clinical Case presentation - "Clinical lymph node metastatic prostate cancer (cN1)"Подробнее

MRIs vs. PSMA PET Scan for Relapsed #ProstateCancer #PCRIПодробнее

Validation of PSMA-PET to the most used nomograms for pelvic lymph-node metastases predictionПодробнее

Treatment strategies for node-positive prostate cancer patients after surgeryПодробнее

Staging Intermediate- and High-risk Prostate Cancer With 18F PSMA/PET/CT vs MRI #cancer #newsПодробнее